COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Comparison of Prilosec OTC® Versus Zegerid® for Gastric Acid Suppression

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00808769
Recruitment Status : Completed
First Posted : December 16, 2008
Results First Posted : April 27, 2011
Last Update Posted : June 1, 2015
Information provided by (Responsible Party):
Procter and Gamble

Brief Summary:
The purpose of this study is to compare Prilosec OTC® and Zegerid® in their effects on gastric acid suppression.

Condition or disease Intervention/treatment Phase
Normal Healthy Subject Population Drug: Zegerid® Drug: Prilosec OTC® Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single (Investigator)
Official Title: Comparison of Prilosec OTC® Versus Zegerid® for Gastric Acid Suppression
Study Start Date : November 2008
Actual Primary Completion Date : December 2008
Actual Study Completion Date : December 2008

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: 1
Drug: Zegerid®
capsule(20 mg omeprazole/sodium bicarbonate), single dose

Experimental: 2
Prilosec OTC®
Drug: Prilosec OTC®
Omeprazole-magnesium 20.6 mg, tablet, single dose

Primary Outcome Measures :
  1. The Mean Percent Time Gastric pH > 4.0 on Day 1 [ Time Frame: continuously over a 24 hour period ]
    In this study, there was evidence of gastric pH probe failure and a high incidence of biologically improbable pH measurements (sustained pH < 1.0) that bring the validity of the results into question. The results of this study are, therefore, inconclusive.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Normal subjects who are 18-65 years of age;
  • Non-childbearing potential females or those using birth control

Exclusion Criteria:

  • History of significant GI disease
  • Any significant medical illness
  • History of hypersensitivity, allergy or intolerance to omeprazole or other proton pump inhibitors;
  • Currently using GI medications
  • GI disorder or surgery leading to impaired drug absorption

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00808769

Layout table for location information
United States, Oklahoma
Research Site
Oklahoma City, Oklahoma, United States, 73104
Sponsors and Collaborators
Procter and Gamble
Layout table for investigator information
Study Director: John McRorie, PhD, FACG, AGAF Procter and Gamble
Layout table for additonal information
Responsible Party: Procter and Gamble Identifier: NCT00808769    
Other Study ID Numbers: 2008122
First Posted: December 16, 2008    Key Record Dates
Results First Posted: April 27, 2011
Last Update Posted: June 1, 2015
Last Verified: May 2015
Additional relevant MeSH terms:
Layout table for MeSH terms
Omeprazole, sodium bicarbonate drug combination
Anti-Ulcer Agents
Gastrointestinal Agents
Proton Pump Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action